Boehringer Ingelheim India Boosts Innovation with NIPER

Boehringer Ingelheim India has signed a landmark MoU with the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, marking a significant step toward advancing pharmaceutical innovation in the country.

The agreement, formalized at the Department of Pharmaceuticals, underscores a growing push to strengthen research-led growth in India’s healthcare sector.

The signing ceremony was attended by Manoj Joshi, Secretary, Department of Pharmaceuticals, along with Awadhesh Kumar Choudhary, Senior Economic Advisor, and Anugraha P, Director, Department of Pharmaceuticals. The collaboration also includes NIPER Raebareli’s Centre of Excellence for Novel Drug Delivery Systems (CoE-NDDS).

Also Read: Bridging Collaboration Gaps to Boost India's Pharma Discovery

Under this MoU, Boehringer Ingelheim India and NIPER Raebareli will work closely on pharmaceutical technologies, novel drug delivery systems, joint research projects, academic exchanges, and capability-building programs. As part of the partnership, Boehringer Ingelheim will provide access to opnMe, its open science portal that connects researchers and institutions to accelerate healthcare innovation. The two sides will also explore symposia, conferences, short-term courses, and scholar engagement initiatives.

Meenal Gauri, Managing Director of Boehringer Ingelheim India, said, “India is entering an important phase in its pharmaceutical journey, moving from scale-led growth to innovation-led impact. At Boehringer Ingelheim, we believe progress in healthcare is accelerated when industry, academia, and public institutions come together.

"This MoU with NIPER Raebareli reflects our commitment to strengthening scientific capability and supporting collaborations that can contribute to better health outcomes for patients and communities.”

Prof. Shubhini A Saraf, Director of NIPER Raebareli, added, “This MoU supports our vision of advancing pharmaceutical education and research while enabling opportunities for students and researchers to contribute to areas of emerging importance such as novel drug delivery systems and community health solutions. We look forward to working with Boehringer Ingelheim to create meaningful opportunities for students and researchers and to contribute to India’s innovation ecosystem.”